| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
ARTD3/PARP3-IN-1 targets diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3), also known as PARP3 (poly(ADP-ribose) polymerase 3). PARP3 is a member of the PARP family that plays roles in DNA double-strand break repair, genome stability, and cellular stress responses. ARTD3/PARP3-IN-1 is an unselective inhibitor of ARTD3/PARP3. It modulates DNA double-strand break repair responses via MARylation (mono-ADP-ribosylation).
|
|---|---|
| ln Vitro |
In vitro, ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3. It modulates DNA double-strand break repair responses via MARylation and is used for genome stability and cell stress research. These in vitro properties make ARTD3/PARP3-IN-1 a valuable tool for studying PARP3 function and its role in DNA repair and cellular stress responses.
|
| ln Vivo |
In vivo activity of ARTD3/PARP3-IN-1 has not been extensively reported. As a PARP3 inhibitor that modulates DNA repair, it may have potential for cancer research, particularly in combination with DNA-damaging agents. However, detailed in vivo efficacy data are limited in publicly available sources. The compound is primarily used as a research tool for studying PARP3 biology.
|
| Enzyme Assay |
The in vitro enzyme assay for ARTD3/PARP3-IN-1 involves measuring its inhibition of PARP3 enzymatic activity. Recombinant PARP3 is incubated with the compound at various concentrations in the presence of NAD+ and a DNA substrate. PARP3 activity is measured by quantifying the incorporation of ADP-ribose into acceptor proteins using radiometric, luminescent, or immunoassay-based methods. The IC50 for PARP3 inhibition is calculated from dose-response curves.
|
| Cell Assay |
The in vitro cell-based assay for ARTD3/PARP3-IN-1 involves culturing cells and treating them with the compound to assess effects on DNA repair and cell stress responses. Cells are treated with ARTD3/PARP3-IN-1 at various concentrations, and PARP3 activity is assessed by measuring MARylation levels by Western blot or immunofluorescence. DNA damage responses can be assessed by measuring γ-H2AX foci formation or comet assays following DNA damage induction. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for ARTD3/PARP3-IN-1 have not been extensively reported. If conducted, such studies might involve mouse xenograft models of cancer, where ARTD3/PARP3-IN-1 is administered alone or in combination with DNA-damaging agents, and tumor growth is monitored. Standard protocols for xenograft studies would be employed. No specific data are available from publicly accessible sources.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of ARTD3/PARP3-IN-1 have not been extensively characterized. As a small molecule with a molecular weight of 308.33 and a molecular formula of C17H16N4O2, it is expected to have moderate oral bioavailability. The compound can be formulated for in vivo administration. Detailed PK parameters such as half-life, Cmax, and bioavailability are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ARTD3/PARP3-IN-1 has not been systematically evaluated. As a PARP3 inhibitor that modulates DNA repair, its primary safety concerns would relate to effects on genome stability and normal cell function. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References |
1: Boehler C, Gauthier LR, Mortusewicz O, Biard DS, Saliou JM, Bresson A, Sanglier-Cianferani S, Smith S, Schreiber V, Boussin F, Dantzer F. Poly(ADP- ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2783-8. doi: 10.1073/pnas.1016574108. Epub 2011 Jan 26. PMID: 21270334; PMCID: PMC3041075. 2: Lindgren AE, Karlberg T, Thorsell AG, Hesse M, Spjut S, Ekblad T, Andersson CD, Pinto AF, Weigelt J, Hottiger MO, Linusson A, Elofsson M, Schüler H. PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3. ACS Chem Biol. 2013 Aug 16;8(8):1698-703. doi: 10.1021/cb4002014. Epub 2013 Jun 25. PMID: 23742272. 3: Lindgren AE, Karlberg T, Ekblad T, Spjut S, Thorsell AG, Andersson CD, Nhan TT, Hellsten V, Weigelt J, Linusson A, Schüler H, Elofsson M. Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68. doi: 10.1021/jm401394u. Epub 2013 Nov 22. PMID: 24188023.
|
| Additional Infomation |
ARTD3/PARP3-IN-1 is a research compound and has not been approved for clinical use. It is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3. The compound modulates DNA double-strand break repair responses via MARylation and is used for genome stability and cell stress research. ARTD3/PARP3-IN-1 is a valuable tool for studying PARP3 function in DNA repair and cellular stress responses.
|
| Molecular Formula |
C17H16N4O2
|
|---|---|
| Molecular Weight |
308.334543228149
|
| Exact Mass |
308.13
|
| Elemental Analysis |
C, 66.22; H, 5.23; N, 18.17; O, 10.38
|
| CAS # |
730949-09-4
|
| PubChem CID |
135520066
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
477
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)NC(=N2)CCC(=O)NCC3=CC=CC=N3
|
| InChi Key |
LHJLGHGHHDKLMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16N4O2/c22-16(19-11-12-5-3-4-10-18-12)9-8-15-20-14-7-2-1-6-13(14)17(23)21-15/h1-7,10H,8-9,11H2,(H,19,22)(H,20,21,23)
|
| Chemical Name |
3-(4-oxo-1,4-dihydroquinazolin-2-yl)-N-(pyridin-2-ylmethyl)propanamide
|
| Synonyms |
ARTD3/PARP3-IN-1; ARTD3; PARP3-IN-1; ARTD3/PARP3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2433 mL | 16.2164 mL | 32.4328 mL | |
| 5 mM | 0.6487 mL | 3.2433 mL | 6.4866 mL | |
| 10 mM | 0.3243 mL | 1.6216 mL | 3.2433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
